Table 2.
Prognostic values of clinical and imaging characteristics in the prediction of PFS.
| Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Age | 0.973 (0.914–1.036) | 0.390 | ||
| ISUP grade | ||||
| ISUP 1 | 1.000 (Ref.) | |||
| ISUP 2 | 0.694 (0.097–4.972) | 0.716 | ||
| ISUP 3 | 0.993 (0.163–6.030) | 0.994 | ||
| ISUP 4 | 1.474 (0.268–8.097) | 0.656 | ||
| ISUP 5 | 1.536 (0.265–8.916) | 0.632 | ||
| Primary treatment (radiotherapy vs. surgery) | ||||
| Surgery | 1.000 (Ref.) | |||
| Radiotherapy (± ADT) | 2.617 (0.784–8.736) | 0.143 | ||
| Previous salvage radiotherapy | 0.698 (0.217–2.243) | 0.546 | ||
| CRPC | 6.238 (1.939–20.073) | 0.002 | 4.587 (1.226–17.154) | 0.024 |
| PSA pre-MDT | 1.005 (0.922–1.095) | 0.907 | ||
| Medical therapy in addition to MDT | 0.635 (0.142–2.843) | 0.553 | ||
| PSA nadir after MDT | 2.979 (1.882–4.717) | <0.001 | 2.937 (1.750–4.928) | <0.001 |
| PET/CT imaging | ||||
| [68Ga]Ga-PSMA-11 | 1.000 (Ref.) | |||
| [18F]F-Fluorocholine | 3.813 (1.351–10.760) | 0.011 | 2.603 (0.829–8.172) | 0.100 |
| SUVmax | 1.031 (0.981–1.084) | 0.232 | ||
| MTV | 0.936 (0.707–1.240) | 0.645 | ||
| TLG | 1.002 (0.977–1.028) | 0.870 | ||
| Number of metastases treated with MDT | ||||
| 1 lesion | 1.000 (Ref.) | |||
| 2 or more lesions | 1.550 (0.532–4.518) | 0.422 | ||
| Site of metastases treated with MDT | ||||
| Lymph node | 1.000 (Ref.) | |||
| Bones or both | 0.926 (0.283–3.031) | 0.899 | ||
| MDT total dose | 0.952 (0.812–1.117) | 0.546 | ||
| MDT biologically effective dose | 0.993 (0.958–1.029) | 0.695 | ||
Univariate and multivariate analyses were performed with the Cox regression model. Significant p-values are bolded. Abbreviations: ADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer; ISUP, International Society of Urological Pathology; MDT, metastasis-directed therapy; MTV, metabolic tumor volume; PET/CT, positron emission tomography/computed tomography; PSA, prostate-specific antigen; SUVmax, maximum standardized uptake value; TLG, total lesion glycolysis.